Spero Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Spero Therapeutics şirketinin toplam hissedar öz sermayesi $65.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $135.2M ve $69.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$76.29m
Eşitlik	US$65.51m
Toplam yükümlülükler	US$69.65m
Toplam varlıklar	US$135.16m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2HA 'nin kısa vadeli varlıkları ( $131.6M ) kısa vadeli yükümlülüklerini ( $49.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: 2HA şirketinin kısa vadeli varlıkları ( $131.6M ) uzun vadeli yükümlülüklerini ( $20.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2HA borçsuzdur.

Borcun Azaltılması: 2HA un 5 yıl önce borcu yoktu.

Borç Kapsamı: 2HA un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 2HA şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Spero Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.061 loss in 3Q 2023)

Investor sentiment improves as stock rises 17%

Spero Therapeutics, Inc. Announces SPR720 Phase 2a Interim Results

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.23 loss in 2Q 2023)

Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.25 loss in 1Q 2023)

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

New major risk - Revenue and earnings growth

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.43 (vs US$1.24 loss in FY 2022)

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

Co-Founder & Chairman of the Board recently sold €81k worth of stock

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.33 loss in 3Q 2022)

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.87 loss in 2Q 2022)

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.25 loss per share (vs US$1.01 loss in 1Q 2022)

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.24 loss per share (vs US$2.91 loss in FY 2021)

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.70 loss in 3Q 2021)

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.63 loss in 2Q 2021)

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

First quarter 2022 earnings released: US$1.01 loss per share (vs US$0.66 loss in 1Q 2021)

Spero Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

Insufficient new directors

Full year 2021 earnings released: US$2.91 loss per share (vs US$3.52 loss in FY 2020)

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206

Spero Therapeutics Receives Up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

Spero Therapeutics, Inc. Announces Lifting of FDA Clinical Trial Hold on SPR720

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem Hbr for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.86 loss in 3Q 2020)

Insufficient new directors

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.85 loss in 2Q 2020)

Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.

Spero Therapeutics, Inc. Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of Spr206

Spero Therapeutics, Inc. Wins Funding of $2.09 Million, with the Potential for Up to an Additional $21.3 Million over 5 Years, from the National Institute of Allergy and Infectious Diseases

First quarter 2021 earnings released: US$0.66 loss per share (vs US$1.22 loss in 1Q 2020)

Full year 2020 earnings released: US$3.52 loss per share (vs US$3.36 loss in FY 2019)

Revenue misses expectations

New 90-day high: €19.00

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Spero Therapeutics Announces Issuance of Allowance for A U.S. Patent Covering Lead Candidate Tebipenem HBr

Everest Medicines Announces Amended Agreement with Spero Therapeutics

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer, Effective as of January 4, 2021

Spero Therapeutics, Inc. Announces First Patient Dosed with SPR720 in Phase 2A Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

New 90-day high: €14.60

Spero Therapeutics, Inc. Appoints Tamara Joseph as Chief Legal Officer

New 90-day high: €12.30